nach oben

Erschienen in:

2019 | OriginalPaper | Buchkapitel

41. Psychopharmaka

verfasst von : Prof. Dr. med. Martin J. Lohse, Prof. Dr. med. Bruno Müller-Oerlinghausen

Erschienen in: Arzneiverordnungs-Report 2019

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Auszug

Trend Die Verordnungsstruktur der Psychopharmaka hat sich in den letzten 10 Jahren auffällig verändert. Im Durchschnitt haben die Verordnungen der Antidepressiva in der letzten Dekade nochmals um mehr als 40 % zugenommen, mit abflachender Tendenz seit 2012. Dieser Anstieg wurde vor allem von den selektiven Serotonin-Rückaufnahme-Inhibitoren (SSRI) und den Serotonin-Noradrenalin-Rückaufnahme-Inhibitoren (SNRI) getragen, während die älteren nichtselektiven Monoamin-Rückaufnahme-Inhibitoren (NSMRI, Trizyklika) seit 2010 in ihrer Verordnung rückläufig waren. …

Abbas S, Ihle P, Adler JB, Engel S, Günster C, Linder R, Lehmkuhl G, Schubert I (2016) Psychopharmaka-Verordnungen bei Kindern und Jugendlichen in Deutschland. Bundesweite Auswertung von über 4 Millionen gesetzlich Versicherten von 2004 bis 2012. Dtsch Arztebl 113:396–403

Abou-Saleh MT, Müller-Oerlinghausen B, Coppen AJ (2017) Lithium in the episode and suicide prophylaxis and in augmenting strategies in patients with unipolar depression. Int J Bipolar Disord 5(1). https://doi.org/10.1186/s40345-017-0080-xCrossRefPubMedPubMedCentral

Aderhold V, Weinmann S, Hägele C, Heinz A (2014) Frontale Hirnvolumenminderung durch Antipsychotika? Nervenarzt 86:302–323

American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596–601

Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58:19–36PubMed

Arnett A, Stein M (2018) Refining treatment choices for ADHD. Lancet Psychiatry 5:691–692PubMed

Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2005) Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3:449–456PubMedPubMedCentral

Arzneimittel-Info (2017) Außer Vertrieb Nortrilen Dragees. Deutsche Apotheker Zeitung 157:133

Arzneimittelkommission der deutschen Ärzteschaft (2004) Suizide und Suizidversuche unter Bupropion. Dtsch Arztebl 101:A 2139–2140

Arzneimittelkommission der deutschen Ärzteschaft (2011) Aus der UAW-Datenbank: Abhängigkeitspotenzial unter Pregabalin (Lyrica^®). Dtsch Arztebl 108:A 183

Azab AN, Shnaider A, Osher Y, Wang D, Bersudsky Y, Belmaker RH (2015) Lithium nephrotoxicity. Int J Bipolar Disord 3:28PubMed

Bachmann CJ, Lempp T, Glaeske G, Hoffmann F (2014) Antipsychotika-Verordnungen bei Kindern und Jugendlichen: Auswertung von Daten einer gesetzlichen Krankenkasse für den Zeitraum 2005–2012. Dtsch Arztebl 111:25–34

Bachmann CJ, Philipsen A, Hoffmann F (2017) ADHS in Deutschland: Trends in Diagnose und medikamentöser Therapie. Dtsch Arztebl 114:141–148

Baghai TC, Lieb M, Möller HJ, Bschor T, Härter M, Schauenburg H (2011) Antidepressiva bei leichten depressiven Störungen. Psychiatr Prax 38:270–273PubMed

Baier A, Bschor T (2019) Warum Antidepressiva-Studien scheitern: Zunehmender Placeboeffekt oder abnehmende Wirksamkeit? Arzneiverordn Prax 46:55–58

Bakota EL, Samms WC, Gray TR, Oleske DA, Hines MO (2018) Case reports of fatalities involving tianeptine in the United States. J Anal Toxicol Mar 16. https://doi.org/10.1093/jat/bky023CrossRefPubMed

Bauer M, Gitlin M (2016) The essential guide to lithium treatment. Springer, Basel

Bauer M, Grof P, Müller-Oerlinghausen B (Hrsg) (2006) Lithium in neuropsychiatry: the comprehensive guide. Informa healthcare, Oxon

Bauer M, Adli M, Bschor T, Pilhatsch M, Pfennig A, Sasse J, Schmid R, Lewitzka U (2010) Lithium’s emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology 62:36–42PubMed

Baumann P, Spies M, Möller HJ, Kasper S, Bitter I, Laux G (2017) A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe. World J Biol Psychiatry 18:29–38PubMed

Bendz H, Schön S, Attman PO, Aurell M (2010) Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 77:219–224PubMed

Blanchflower D, Oswald A (2016) Antidepressants and age: A new form of evidence for U-shaped well-being through life. J Econonomic Behav Organ 127:46–58

Bocchetta A, Ardau R, Carta P, Ligas F, Sardu C, Pani A, Del Zompo M (2013) Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study. Bmc Med 2013 Feb 11(11):33. https://doi.org/10.1186/1741-7015-11-33CrossRefPubMed

Braun C, Bschor T, Franklin J, Baethge C (2016) Suicides and suicide attempts during long-term treatment with antidepressants: a meta-analysis of 29 placebo-controlled studies including 6,934 patients with major depressive disorder. Psychother Psychosom 85:171–179PubMed

Bschor T, Adli M (2009) Therapie depressiver Erkrankungen. Dtsch Arztebl 105:A 782–A 792

Bschor T, Hartung HD (2008) Antidepressiva Kombinationsbehandlungen. In: Bschor T (Hrsg) Behandlungsmanual therapieresistenter Depressionen. Kohlhammer, Stuttgart, S 86–101

Bschor T, Müller-Oerlinghausen B (2014) Antidepressiva verringern nicht das Risiko von Suiziden oder Suizidversuchen bei depressiven Patienten: Eine Entgegnung zur Presseerklärung der Deutschen Gesellschaft für Psychiatrie, Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). Arzneiverordn Prax 41(2):2–4

Bschor T, Müller-Oerlinghausen B, Stoppe G, Hiemke C (2014) Neue Fakten zur Phasenprophylaxe der bipolar affektiven Erkrankung. Nervenarzt 85:1166–1170PubMed

Bundesinstitut für Arzneimittel und Medizinprodukte (2016) Leitfaden für Ärzte zur Verordnung von Quetiapin-haltigen Arzneimitteln. https://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/Risikoinformationen/Schulungsmaterial/Wirkstoff/_node_Wirkstoff.html

Cipriani A, Rendell J, Geddes JR (2010) Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol 24:1729–1738PubMed

Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C (2012) Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012 Oct 17; (10): CD006533

Cipriani A, Hawton K, Stockton S, Geddes JR (2013) Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 346:f3646. https://doi.org/10.1136/bmj.f3646CrossRefPubMed

Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391:1357–1366PubMedPubMedCentral

Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002) Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28:75–84PubMed

Connolly KR, Thase ME (2011) If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 71:43–64PubMed

Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5:727–738PubMedPubMedCentral

Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J (2011) Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 343:d4551. https://doi.org/10.1136/bmj.d4551CrossRefPubMedPubMedCentral

Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J (2015) Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. BMJ 2015 Feb 18(350):h517. https://doi.org/10.1136/bmj.h517CrossRef

Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG (2015) Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 385:2190–2196PubMed

Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J (2016) Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults – a Swedish nationwide study. Br J Clin Pharmacol 81:773–783PubMedPubMedCentral

Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Kahn RS (2009) Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166:675–682PubMed

Dersch R, Zwernemann S, Voderholzer U (2011) Partial status epilepticus after electroconvulsive therapy and medical treatment with bupropion. Pharmacopsychiatry 44:344–346PubMed

Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (2015) S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression, 2. Auflage, AWMF-Register-Nr.: nvl-005. www.depression.versorgungsleitlinien.de

Deutsche Gesellschaft für Soziale Psychiatrie (DGSP) (2009) DGSP-Memorandum zur Anwendung von Antipsychotika. Soziale Psychiatr 34:50–51

European Medicines Agency (2019) PRAC recommendations on signals. Adopted at the 13–16 May 2019 PRAC meeting. 1. Recommendations for update of the product information. https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-13-16-may-2019-prac-meeting_en.pdf (1.3. Serotonin and noradrenaline reuptake inhibitors (SNRI)4; selective serotonin reuptake inhibitors (SSRI), (SNRI)4; selective serotonin reuptake inhibitors (SSRI))

Food and Drug Administration (2016) FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada). https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-new-impulse-control-problems-associated-mental-health

Fountoulakis KN, Möller HJ (2010) Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 14:405–412PubMed

Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J (2010) Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303:47–53PubMedPubMedCentral

Frampton JE (2018) Lisdexamfetamine dimesylate: a review in paediatric ADHD. Drugs 2018 Jun 19. https://doi.org/10.1007/s40265-018-0936-0CrossRefPubMedPubMedCentral

Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM (2000) The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61:9–15PubMed

Gahr M, Hiemke C, Connemann BJ (2017) Update Opipramol. Fortschr Neurol Psychiatr 85:139–145PubMed

Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN (2008) Comparative benefits and harms of second-generation antidepressants: background paper for the American college of physicians. Ann Int Med 149:734–750PubMed

Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Brit Med J 321:1371–1376PubMed

Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2001) SSRIs versus other antidepressants for depressive disorder. Update Software Ltd Oxford. Cochrane Libr (1)

Gerhard T, Huybrechts K, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, Devanand DP, Lucas JA, Huang C, Malka ES, Levin R, Crystal S (2014) Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry 205:44–51PubMed

Gibbons RD, Brown CH, Hur K, Marcus SM, Baumikh DK, Erkenmann JJ (2007) Early evidence on the effects of regulators’ suicidality warnings on prescriptions and suicide in children and adolescents. Am J Psychiatry 164:1356–1363PubMed

Goldberg TE, Gomar JJ (2009) Targeting cognition in schizophrenia research: from etiology to treatment. Am J Psychiatry 166:631–634PubMed

Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003) Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290:1467–1473PubMed

Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R (2004) A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65:432–441PubMed

Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T (1996) Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J Affect Disord 40:179–190PubMed

Grof P, Müller-Oerlinghausen B (2009) A critical appraisal of lithium’s efficacy and effectiveness: the last 60 years. Bipolar Disord 11(Suppl 2):10–19PubMed

Grohmann R, Engel RR, Geissler KH, Rüther E (2004) Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 37(Suppl 1):S27–38PubMed

Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M (2013) Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev 2013 Dec 17; (12): CD008851

Hägg S, Bate A, Stahl M, Spigset O (2008) Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Saf 31:685–694PubMed

Hansen R, Gaynes B, Thieda P, Gartlehner G, Deveaugh-Geiss A, Krebs E, Lohr K (2008) Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv 59:1121–1130PubMedPubMedCentral

Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP (2016) Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry 15:53–58PubMedPubMedCentral

Heal DJ, Smith SL, Gosden J, Nutt DJ (2013) Amphetamine, past and present – a pharmacological and clinical perspective. J Psychopharmacol 27:479–496PubMedPubMedCentral

Healy D (2003) Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72:71–79PubMed

Hegerl U, Mergl R, Quail D, Schneider E, Hundemer HP, Linden M (2012) Does pain improve earlier than mood in depressed patients with painful physical symptoms treated with duloxetine? Pharmacopsychiatry 45:114–118PubMed

Hengartner MP, Angst J, Rössler W (2018) Antidepressant use prospectively relates to a poorer long-term outcome of depression: results from a prospective community cohort study over 30 years. Psychother Psychosom 87:181–183PubMed

Henssler J, Heinz A, Brandt L, Bschor T (2019) Absetz- und Rebound-Phänomene bei Antidepressiva. Dtsch Arztebl 116:355–361

Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44:195–235PubMed

Hwang YJ, Dixon SN, Reiss JP, Wald R, Parikh CR, Gandhi S, Shariff SZ, Pannu N, Nash DM, Rehman F, Garg AX (2014) Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med 161:242–248PubMed

Institut für Arzneimittelsicherheit in der Psychiatrie (AMSP e.V.) (2018) Multicenterstudie zu Nebenwirkungen in der Gerontopsychiatrie. https://amsp.de/amsp-projekt/aktuelle-projekte/

Janhsen K, Roser P, Hoffmann K (2015) Probleme der Dauertherapie mit Benzodiazepinen und verwandten Substanzen. Dtsch Arztebl 112:1–7

Jans T, Warnke A (2010) Die britische NICE-Guidance zu Diagnose und Therapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter. Arzneiverordn Prax 37:4–6

Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, Leese M, McCrone P, Harris T, Moore M, Byng R, Brown G, Barthel S, Mander H, Ring A, Kelly V, Wallace V, Gabbay M, Craig T, Mann A (2009) Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technol Assess 13(iii–iv, ix–xi):1–159

Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefit: a meta-analysis of data submitted to the Food and Drug Administration. Plos Med 5:e45PubMedPubMedCentral

Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, Kissling W, Leucht S (2009) Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009 Oct 7; (4):CD006569

Komossa K, Depping AM, Meyer M, Kissling W, Leucht S (2010) Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev 2010 Dec 8; (12): CD008141

Lepping P, Sambhi RS, Whittington R, Lane S, Poole R (2011) Clinical relevance of findings in trials of antipsychotics: systematic review. Br J Psychiatry 198:341–345PubMed

Leucht S, Wahlbeck K, Hamann J, Kissling W (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581–1589PubMed

Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009a) How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14:429–447PubMed

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009b) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41PubMed

Lewitzka U, Bauer M, Felber W, Müller-Oerlinghausen B (2013) Suizidprophylaktische Wirkung von Lithium. Aktueller Forschungsstand und Implikationen für die Therapie affektiver Störungen. Nervenarzt 84:294–306PubMed

Lewitzka U, Severus E, Bauer R, Ritter P, Müller-Oerlinghausen B, Bauer M (2015) The suicide protective effects of lithium: more than 20 years of evidence. Int J Bipol Dis 3:1–15

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1233PubMed

Linde K, Kriston L, Rücker G, Jamil S, Schumann I, Meissner K, Sigterman K, Schneider A (2015) Efficacy and acceptability of pharmacological treatments for ndepressive disorders in primary care: a systematic review and network meta-analysis. Am Fam Med 13:69–79

MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2003) Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. Brit Med J 326:1014–1019PubMed

Macritchie KAN, Geddes MR, Scott J, Haslam DRS, Goodwin GM (2001) Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorders. Cochrane Review. Cochrane Libr (3)

Maher AR, Theodore G (2012) Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 18(5 Suppl B):S1–20PubMed

Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG (2011) Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306:1359–1369PubMed

McDonagh M, Peterson K, Carson S, Fu R, Thakurta S (2010) Drug Class Review: Atypical Antipsychotic Drugs. Final Update 3 Report. Portland (OR): Oregon Health & Science University; July 2010. http://www.ncbi.nlm.nih.gov/books/NBK50583/

McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, CATIE Investigators (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600–610PubMed

McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS (2014) Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 311:1978–1987PubMedPubMedCentral

McGorry P, Alvarez-Jimenez M, Killackey E (2013) Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. JAMA Psychiatry 70:898–900PubMed

McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR (2012) Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379:721–728PubMed

Mészáros A, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I (2009) Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol 12:1137–1147PubMed

Miyamoto S, Miyake S, Jarskog LF, Fleischhacker WW, Lieberman JA (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17:1206–1227PubMed

Molina BSG, Florey K, Hinshaw SP, Greiner AR, Arnold E, Swanson JM, Hechtman L, Jensen PS, Vitiello B, Hoza B, Pelham WE, Elliot GR, Wells KC, Abikoff HB, Gibbons RD, Marcus S, Conners CK, Epstein JN, Greenhill LL, March JS, Newcorn JH, Severe JB, Wigal T (2007) Delinquent behavior and emerging substance use in the MTA at 36 months: Prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 46:1028–1040PubMed

Moncrieff J (2008) Steht die Psychiatrie zum Verkauf an? Sozialpsychiatr Informationen 38:8–18

Moncrieff J, Kirsch I (2005) Efficacy of antidepressants in adults. BMJ 331:155–157PubMedPubMedCentral

MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1073–1086

Müller-Oerlinghausen B (2011) Antidepressiva sind nur bei sehr schwerer Depression Placebo überlegen. Arzneiverordn Prax 39:60–62

Müller-Oerlinghausen B (2012) Sind atypische Antipsychotika Mittel erster Wahl bei bipolaren Störungen? Kontra. Nervenarzt 83:1191–1192PubMed

National Institute for Health and Care Excellence (2014) Psychosis and schizophrenia in adults: prevention and management. Clinical guideline. nice.org.uk/guidance/cg178

Niedrig DF, Gött C, Fischer A, Müller ST, Greil W, Buckler G, Russmann S (2016) Second-generation antipsychotics in a tettiary care hospital: prescribing patterns, metabolic profiles, and drug interactions. Int Clin Psychopharmacol 31:42–50PubMed

Niklewski G, Niklewski R, Glaeske G, Günther J, Müller-Oerlinghausen B (2018) Medikamente im Test – Depressionen & Burnout. Therapie auf dem Prüfstand. Stiftung Warentest, Berlin (160 Seiten)

Offidani E, Fava GA, Tomba E, Baldessarini RJ (2013) Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. Psychother Psychosom 82:132–141PubMed

Pike E, Leiknes KA, Wisløff T, Ringerike T, Gjertsen MK (2009) Efficacy and safety of first-generation and second-generation anti-psychotic drugs for schizophrenia in adults: An overview of systematic reviews. Report from Norwegian knowledge centre for the health services (NOKC), Bd. 08-2009. Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH), Oslo (2009 May)

Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK, Clinical Efficacy Assessment Subcommittee of American College of Physicians (2008) Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149:725–733PubMed

Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360:225–235PubMedPubMedCentral

Reeves RR, Ladner ME (2010) Antidepressant-induced suicidality: an update. Cns Neurosci Ther 16:227–234PubMedPubMedCentral

Remschmidt H, Working Group (2005) Global consensus on ADHD/HKD. Eur Child Adolesc Psychiatry 14:127–137PubMed

Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG, DIADS-2 Research Group (2010) Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 18:136–145PubMedPubMedCentral

Rybakowski JK, Suwalska A, Hajek T (2018) Clinical perspectives of lithium’s neuroprotective effect. Pharmacopsychiatry 51:194–199

Sayadipour A, Mago R, Kepler CK, Chambliss RB, Certa KM, Vaccaro AR, Albert TJ, Anderson DG (2012) Antidepressants and the risk of abnormal bleeding during spinal surgery: a case-control study. Eur Spine J 21:2070–2078PubMedPubMedCentral

Schubert I, Lehmkuhl G (2017) Verlauf und Therapie von ADHS und der Stellenwert im Erwachsenenalter. Dtsch Arztebl 114:139–140

Schueler YB, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T, Becker T, Weinmann S (2011) A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 123:247–265PubMed

Sharma T, Guski LS, Freund N, Gøtzsche PC (2016) Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ 2016 Jan 27(352):i65. https://doi.org/10.1136/bmj.i65CrossRef

Shine B, McKnight RF, Geddes JR (2015) Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 386:461–468PubMed

Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA (2008) Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420–1431PubMed

Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N (2019) Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 393:768–777PubMed

Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002) Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180:396–404PubMed

Smith EG, Austin KL, Kim HM, Eisen SV, Kilbourne AM, Miller DR, Zivin K, Hannemann C, Sauer BC, Valenstein M (2015) Mortality associated with lithium and valproate treatment of US veterans health administration patients with mental disorders. Br J Psychiatry 207:55–63PubMed

Song HR, Kwon YJ, Woo YS, Bahk WM (2015) Effects of mirtazapine on patients undergoing naturalistic diabetes treatment: a follow-up study extended from 6 to 12 months. J Clin Psychopharmacol 35:730–731PubMed

Song J, Sjölander A, Joas E, Bergen SE, Runeson B, Larsson H, Landén M, Lichtenstein P (2017) Suicidal behavior during lithium and valproate treatment: a within-individual 8-year prospective study of 50,000 patients with bipolar disorder. Am J Psychiatry 174:795–802PubMed

Soyka M, Lieb M (2015) Recent developments in pharmacotherapy of alcoholism. Pharmacopsychiatry 48:123–135PubMed

Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013) Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. Plos Med 10(3):e1001403PubMedPubMedCentral

Sterke CS, Ziere G, van Beeck EF, Looman CW, van der Cammen TJ (2012) Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia. Br J Clin Pharmacol 73:812–820PubMedPubMedCentral

Stone DM, Simon TR, Fowler KA, Kegler SR, Yuan K, Holland KM, Ivey-Stephenson AZ, Crosby AE (2018) Vital signs: Trends in state suicide rates – United States, 1999–2016 and circumstances contributing to suicide – 27 states, 2015. Mmwr Morb Mortal Wkly Rep 67:617–624PubMedPubMedCentral

Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C (2015) Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev 2015 Nov 25; (11): CD009885

Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A (2018) Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother 19:1057–1070

Stübner S, Grohmann R, Greil W, Zang X, Müller-Oerlinghausen B et al (2018) Update: Suicidal ideation and suicidal behaviour as rare events of antidepressant medication. Report from the AMSP Multcenter Drug Safety Surveillance Project. Int J Neuropharmacol 21:814–821

Tandon R, Jibson MD (2003) Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28:9–26PubMed

Toffol E, Hätönen T, Tanskanen A, Lönnqvist J, Wahlbeck K, Joffe G, Tiihonen J, Haukka J, Partonen T (2016) Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study. J Affect Disord 183:159–165

La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M (2014) Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry 46:201–208

Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E (2008) Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 31:7–20PubMed

Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielmans GI, Healy D (2011) Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. Plos Med 8:e1000434PubMedPubMedCentral

Tsapakis EM, Gamie Z, Tran GT, Adshead S, Lampard A, Mantalaris A, Tsiridis E (2012) The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry 27:156–169PubMed

Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358:252–260PubMed

Ujeyl M, Müller-Oerlinghausen B (2012) Antidepressiva zur Behandlung der Depression bei Palliativpatienten: Eine systematische Übersicht. Schmerz 26:523–536PubMed

Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C (2009) Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 19:629–635PubMed

Wagstaff AJ, Ormrod D, Spencer CM (2001) Tianeptine: a review of its use in depressive disorders. CNS Drugs 15:231–259PubMed

Walder A, Greil W, Baumann P (2009) Drug-induced Pisa syndrome under quetiapine. Prog Neuropsychopharmacol Biol Psychiatry 33:1286–1287PubMed

Wang C, Shi W, Huang C, Zhu J, Huang W, Chen G (2017) The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial. Ann Gen Psychiatry 16:47PubMedPubMedCentral

Wensel TM, Powe KW, Cates ME (2012) Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother 46:424–429PubMed

Whitaker R (2010) Anatomy of an epidemic. Magic bullets, psychiatric drugs, and the astonishing rise of mental illness in America. Crown Publishing, New York

Wolter DK (2009) Risiken von Antipsychotika im Alter, speziell bei Demenzen. Eine Übersicht. Z Gerontopsychol Psychiatr 22:17–56

Zwanzger P (2016) Pharmakotherapie bei Angsterkrankungen. Fortschr Neurol Psychiatr 84:306–314

Titel: Psychopharmaka
verfasst von: Prof. Dr. med. Martin J. Lohse
Prof. Dr. med. Bruno Müller-Oerlinghausen
Verlag: Springer Berlin Heidelberg
Buch: Arzneiverordnungs-Report 2019
Print ISBN: 978-3-662-59045-4

Electronic ISBN: 978-3-662-59046-1

Copyright-Jahr: 2019
DOI: https://doi.org/10.1007/978-3-662-59046-1_41

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

41. Psychopharmaka

Auszug

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin